Viridian Therapeutics, Inc./DE
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $166.6M | $30.9M |
| Jun 2022 | $4.6M | $141.9M | $31.3M |
| Sep 2022 | $4.6M | $409.0M | $344.2M |
| Dec 2022 | $4.6M | $395.1M | $155.6M |
| Mar 2023 | $4.7M | $350.5M | $88.5M |
| Jun 2023 | $4.7M | $315.9M | $87.1M |
| Sep 2023 | $20.0M | $283.6M | $111.6M |
| Dec 2023 | $20.2M | $442.0M | $102.8M |
| Mar 2024 | $20.3M | $582.5M | $91.6M |
| Jun 2024 | $17.5M | $529.3M | $107.7M |
| Sep 2024 | $20.5M | $707.5M | $200.3M |
| Dec 2024 | $20.6M | $671.6M | $99.6M |
| Mar 2025 | $20.7M | $604.5M | $116.2M |
| Jun 2025 | $12.4M | $515.2M | $117.3M |
| Sep 2025 | $20.9M | $503.0M | $169.6M |
| Dec 2025 | — | $722.2M | $212.4M |
| Mar 2026 | — | $636.0M | $176.3M |
| Jun 2026 | — | $662.1M | $165.0M |